Profounds Tulsa system allows for a minimally invasive, whole-gland ablation of the prostate, which will be guided by Philips MRI machines, the companies said.
“Our agreement with Philips will enable us to increase our reach of this unique technology to more clinicians and their patients requiring prostate care. I am convinced that our Tulsa technology will be a valuable addition to Philips’ expanding interventional oncology portfolio,” Profound CEO Steve Plymale said in a press release.
Under the new agreement, the companies will collaborate to commercialize the Tulsa-Pro device in Europe, followed by Canada and the U.S., Philips said.
“Magnetic Resonance Imaging or MRI is emerging as a powerful tool in oncology. For example, MRI has an essential role to play in the diagnosis, treatment and monitoring of prostate cancer. Our collaboration with Profound Medical in MRI-guided therapy further extends our portfolio of treatment technologies that we can offer to advance prostate cancer care,” Philips MR therapy GM Christopher Busch said in a prepared statement.
Treatment with Profound’s Tulsa device requires only a single session and has comparable outcomes to the best alternative treatment options, the companies said.
Last July, Philips and Profound inked a deal to use Profound’s Tulsa-Pro system to treat prostate cancer patients in conjunction with Philips’ Ingenia and Achieva 3 tesla MRI systems.